This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Where Does VKTX Stock Stand After the Obesity Pill Setback?
by Sundeep Ganoria
Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
by Zacks Equity Research
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
RHHBYNegative Net Change BMYPositive Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
by Ekta Bagri
Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change BNTXNo Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
by Zacks Equity Research
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.
NVSPositive Net Change JNJPositive Net Change PFEPositive Net Change LLYPositive Net Change BAYRYPositive Net Change
pharmaceuticals
Encompass Health Opens New Rehabilitation Hospital in The Villages
by Zacks Equity Research
EHC expands in Central Florida with a new 50-bed rehab hospital in The Villages, boosting its growth and patient care network.
THCPositive Net Change INFUPositive Net Change EHCPositive Net Change NVSTPositive Net Change
medical pharmaceuticals
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
LLYPositive Net Change NVSPositive Net Change JNJPositive Net Change PFEPositive Net Change BAYRYPositive Net Change
pharmaceuticals
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
by Zacks Equity Research
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
NVSPositive Net Change NVONegative Net Change ARWRPositive Net Change TRMLPositive Net Change
biotechnology biotechs medical pharmaceuticals
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
by Kinjel Shah
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
AZNPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Is NVO's Major Restructuring Plan an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk's sweeping restructuring plan cuts 9,000 jobs, targets DKK 8 billion in savings, and shifts focus to obesity and diabetes R&D.
NVONegative Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach and SIFCO Industries
by Zacks Equity Research
Zacks highlights Johnson & Johnson, SAP, Coca-Cola, Hamilton Beach, and SIFCO Industries in its latest research roundup, showcasing both blue-chip resilience and micro-cap growth stories.
KONegative Net Change JNJPositive Net Change SAPPositive Net Change HBBPositive Net Change SIFPositive Net Change
aerospace computers consumer-discretionary consumer-staples pharmaceuticals
Top Stock Reports for Johnson & Johnson, SAP & Coca-Cola
by Mark Vickery
Zacks Research Daily spotlights Johnson & Johnson, SAP, and Coca-Cola three global leaders navigating growth opportunities and near-term headwinds.
KONegative Net Change JNJPositive Net Change CEGPositive Net Change APHPositive Net Change SAPPositive Net Change MMCPositive Net Change HBBPositive Net Change SIFPositive Net Change
aerospace computers consumer-discretionary consumer-staples pharmaceuticals
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
by Zacks Equity Research
Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.
BMYPositive Net Change MRKPositive Net Change SMMTPositive Net Change BNTXNo Net Change
biotechs medical pharmaceuticals
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
by Zacks Equity Research
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
AZNPositive Net Change JNJPositive Net Change LLYPositive Net Change ABBVPositive Net Change
pharmaceuticals
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
by Ahan Chakraborty
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
AZNPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx posts 96-week data showing DTX401 sharply cuts cornstarch needs and improves life quality in GSDIa patients.
RAREPositive Net Change CRMDPositive Net Change KNSAPositive Net Change PHARNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?
by Kanishka Das
MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change
pharmaceuticals
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
by Ahan Chakraborty
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
ALNYNegative Net Change PFEPositive Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
by Kinjel Shah
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
BMYPositive Net Change PFEPositive Net Change LLYPositive Net Change ABBVPositive Net Change ALLOPositive Net Change RLAYPositive Net Change PYXSPositive Net Change
cancer pharmaceuticals
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
by Kinjel Shah
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change ABBVPositive Net Change
pharmaceuticals
Take the Zacks Approach to Beat the Markets: Hecla Mining, GE Aerospace & Stride in Focus
by Santanu Roy
Zacks highlights Hecla Mining, GE Aerospace, and Stride as standout performers in a volatile market, driven by earnings trends and stock upgrades.
GENegative Net Change JNJPositive Net Change HDPositive Net Change SENegative Net Change AZOPositive Net Change MTDNegative Net Change HLPositive Net Change LRNPositive Net Change KARPositive Net Change SHOPNegative Net Change NOBLPositive Net Change SHLSPositive Net Change
aerospace alt-energy auto-tires-trucks computers consumer-discretionary internet medical-devices pharmaceuticals retail
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
by Ekta Bagri
Black Diamond shines with a 51.1% stock surge, fueled by silevertinib's progress and pipeline momentum in oncology.
AZNPositive Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Apple, Novartis, Charles Schwab, Community Bancorp and Optex Systems
by Zacks Equity Research
Zacks spotlights Apple, Novartis, Charles Schwab, Community Bancorp, and Optex Systems as key movers, with microcap standouts delivering outsized gains.
NVSPositive Net Change AAPLNegative Net Change SCHWPositive Net Change CMTVNo Net Change OPXSPositive Net Change
pharmaceuticals
RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress
by Zacks Equity Research
Roche posts strong new data for Vabysmo in eye disease, with extended dosing and vision gains driving growth.
REGNPositive Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Top Stock Reports for Apple, Novartis & Charles Schwab
by Mark Vickery
Apple grows Services to 1B+ paid subscribers, while Novartis lifts guidance and Schwab rides higher rates to asset gains.
NVSPositive Net Change AAPLNegative Net Change WDCNegative Net Change SCHWPositive Net Change EWPositive Net Change KMBPositive Net Change CMTVNo Net Change OPXSPositive Net Change
aerospace computers finance pharmaceuticals
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?
by Tirthankar Chakraborty
Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.
NVSPositive Net Change PFEPositive Net Change LLYPositive Net Change
pharmaceuticals